Facial Lipoatrophy Trial: Immediate Versus Deferred Injections of Poly-L-Lactic Acid for HIV Facial Lipoatrophy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE4

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-11-30

Study Completion Date

2007-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a multi-centre, open-label, 96 week study to evaluate the safety, tolerability and extent and duration of improvement in HIV-1 infected subjects with antiretroviral induced facial lipoatrophy, randomised in a 1:1 ratio to receive immediate or deferred deep subcutaneous injections of poly-L-lactic acid (PLA). Subjects will receive 4 treatments of PLA approximately every 2nd week, either at trial entry or following a delay period of 24 weeks.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety and Efficacy of Intradermal Injections of Newfill Versus Eutrophill in the Treatment of Facial Lipoatrophy in HIV-infected Patients ANRS 132 SMILE

NCT00383734

HIV-Associated Lipodystrophy Syndrome

COMPLETED PHASE3

Polyacrylamide Hydrogel Injection in HIV-related Lipoatrophy

NCT01077765

HIV Infection Antiretroviral Side Effects Lipodystrophy Syndrome Related to HIV Infection

COMPLETED PHASE3

Artefill for the Treatment of HIV-associated Facial Lipoatrophy

NCT02009462

HIV-facial Lipoatrophy

COMPLETED PHASE1

Effect of Pioglitazone on HIV-1 Related Lipoatrophy: a Randomized, Double Blind, Placebo-Controlled Trial in 130 Patients

NCT00148850

HIV-Associated Lipodystrophy Syndrome HIV Infections

TERMINATED PHASE3

Randomized, Placebo-Controlled Study of Leptin for the Treatment of HIV Lipodystrophy and Metabolic Syndrome

NCT00140244

HAART-induced Lipodystrophy and Metabolic Syndrome

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

HIV lipodystrophy can be distressing and result in suboptimal antiretroviral (ART) adherence. Physical changes may stigmatise subjects while the negative psychological and social impact has become a major concern. To date, as there is no proven therapy for lipoatrophy, cosmetic interventions for facial lipoatrophy are being studied. Poly-L-lactic acid (PLA) has been shown to be both safe and effective when administered by injection to facial areas.

Study aims are:

1. to evaluate the extent and duration of improvement in HIV facial lipoatrophy of PLA injections;
2. to evaluate the impact of PLA injections on quality of life and ART adherence in subjects with HIV facial lipoatrophy;
3. to evaluate the safety and tolerability of polylactic acid.

100 HIV-infected ART-experienced subjects with facial lipoatrophy will be randomised in a 1:1 ratio at study entry to receive either immediate or deferred treatment (delayed 24 weeks) treatment with PLA. Randomisation will be stratified by age, severity of facial lipoatrophy, current ART (PI or non-PI containing and thymidine- or non-thymidine-containing) and surgeon.

The study has clinical end points monitoring CD4 cell counts, viral loads and adverse events. The study also has psychosocial end points monitoring quality of life.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV-Associated Lipodystrophy HIV Infections

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Immediate

poly-L-lactic acid injections

Group Type EXPERIMENTAL

poly-L-lactic acid

Intervention Type DEVICE

immediate injections poly-L-lactic acid (4 bilateral treatments - 8 vials)

Delayed

poly-L-lactic acid injections

Group Type ACTIVE_COMPARATOR

poly-L-lactic acid

Intervention Type DEVICE

delayed (24 weeks) poly-L-lactic acid injections (4 bilateral treatment - 8 vials)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

poly-L-lactic acid

immediate injections poly-L-lactic acid (4 bilateral treatments - 8 vials)

Intervention Type DEVICE

poly-L-lactic acid

delayed (24 weeks) poly-L-lactic acid injections (4 bilateral treatment - 8 vials)

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Sculptra Sculptra

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Aged 18 years or more with laboratory evidence of HIV-1 infection
* Received combination antiretroviral therapy (minimum of 2 agents)
* Antiretroviral regimen should be stable for at least 12 weeks prior to entry with no changes planned during the first 48 weeks. For subjects not on antiretroviral therapy at entry there should be no intent to commence therapy in first 24 weeks.
* Moderate or severe facial lipoatrophy and lipodystrophy at one or more other sites
* Provide written, informed consent.

Exclusion Criteria

* Active AIDS-defining illness including active HIV wasting
* Active herpes labialis or any acute or currently present chronic skin disease (infection/inflammation) on/near area to be treated
* Currently on anticoagulants or any coagulopathy that would preclude safe deep subcutaneous injections
* Women: pregnant, breastfeeding or have positive pregnancy test or not willing to use adequate contraception if of child-bearing potential
* Concomitant therapy with anabolic steroids (except testosterone replacement), corticosteroids at greater than replacement doses, growth hormone or any currently available or experimental agent to improve appetite or weight
* Testosterone replacement for less than 6 months or at greater than replacement doses
* Subjects who have discontinued any prohibited concomitant agent/s must cease this therapy at least 30 days prior to screening.
* Prior use of any facial dermal filling/tissue expansion agent/s
* Any condition which may interfere with ability to comply with study requirements.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

The National Centre in HIV Epidemiology and Clinical Research

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Andrew Carr, A/Prof

Role: PRINCIPAL_INVESTIGATOR

Immunology and Infectious Disease Unit, St. Vincent's Hospital, Sydney

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Dr Doong's Surgery

Burwood, New South Wales, Australia

Site Status